PUBLISHER: The Business Research Company | PRODUCT CODE: 1670301
PUBLISHER: The Business Research Company | PRODUCT CODE: 1670301
Messenger ribonucleic acid (mRNA) synthesis raw materials comprise ribonuclear components crucial for the precise and efficient creation of mRNA molecules in in-vitro transcription procedures, facilitating the production of functional synthetic RNAs. These materials play a pivotal role in generating mRNA vaccines that trigger the body's immune system to produce a defense response against specific antigens, thereby enhancing overall immune capacity.
Key components of mRNA synthesis raw materials encompass capping agents, nucleotides, plasmid DNA, among others. Capping agents, for instance, are amphiphilic molecules featuring a polar head group and a non-polar hydrocarbon tail. These agents are utilized in introducing modified cap structures to mRNA molecules during synthesis, imparting stability and protection to the mRNA. This enhances translation efficiency and fortifies the mRNA against degradation. These materials find diverse applications in therapeutics and vaccine production and are commonly employed by biotechnology firms, pharmaceutical companies, research institutions, and similar entities.
The mRNA synthesis raw materials market research report is one of a series of new reports from The Business Research Company that provides mRNA synthesis raw materials market statistics, including mRNA synthesis raw materials industry global market size, regional shares, competitors with mRNA synthesis raw materials market share, detailed mRNA synthesis raw materials market segments, market trends, and opportunities, and any further data you may need to thrive in the mRNA synthesis raw materials industry. This mRNA synthesis raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The messenger ribonucleic acid (mRNA) synthesis raw materials market size has grown steadily in recent years. It will grow from $2.99 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 2.5%. The growth in the historic period can be attributed to biomedical research advancements, rising interest in vaccines and therapeutics, demand for personalized medicine, outbreak preparedness and response, and biotech industry growth
The messenger ribonucleic acid (mRNA) synthesis raw materials market size is expected to see steady growth in the next few years. It will grow to $3.54 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to supply chain optimization, commercialization and market expansion, investments in biotech and pharma, regulatory support and approvals, and therapeutic expansion. Major trends in the forecast period include the emergence of new entrants, quality control and standardization, intellectual property and licensing, global access and equity, shift towards sustainable and scalable manufacturing.
The rising prevalence of cancer and chronic disorders is anticipated to drive the growth of the mRNA synthesis raw materials market in the future. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and potentially spread to other parts of the body through the blood and lymphatic systems. Chronic disorders are generally defined as conditions that last for a year or longer, require ongoing medical treatment, hinder daily activities, or both. Raw materials for mRNA synthesis are utilized in drug discovery, vaccine development, and the production of RNA-based therapeutics to enhance immunogenicity, improve efficiency, and shorten production times for treating cancer and chronic diseases. For example, according to the American Cancer Society Facts and Figures, a US-based health organization, an estimated 1.9 million new cancer cases were diagnosed in the US in 2022, resulting in 609,360 deaths. Projections for 2023 indicate a slight increase to over 1.9 million new cases and approximately 609,820 deaths. Therefore, the rising incidence of cancer and chronic disorders is driving the demand for mRNA synthesis raw materials.
Government initiatives supporting mRNA technology are poised to drive the growth of the mRNA synthesis raw materials market. These initiatives encompass coordinated efforts, programs, policies, and financial backing by governmental entities to promote research, development, and application of Messenger RNA (mRNA) technology. Such government support creates a conducive environment for the mRNA synthesis raw materials market by providing funding, infrastructure, regulatory backing, and opportunities for global collaboration. As of February 2023, The BMJ reported that the US government has invested $31.9 billion in mRNA COVID-19 vaccines post-pandemic. Despite financial support, it is noteworthy that the costs for mRNA vaccines from companies such as Pfizer-BioNTech and Moderna have increased over time, reflecting the evolving landscape of vaccine pricing. Specifically, the pricing per dose for Pfizer-BioNTech's vaccine increased from $19.50 in 2020 to $30.48 for the bivalent booster in 2022, while Moderna's costs rose from $15.25 per dose in 2020 to $26.36 in 2022. Hence, government initiatives for mRNA technology play a pivotal role in propelling the growth of the mRNA synthesis raw materials market.
The mRNA synthesis raw materials market is witnessing a notable trend with the increasing emphasis on product innovations. Key players in this market are strategically focusing on the development of innovative products to enhance their market positioning. An illustrative example is Thermo Fisher Scientific, a prominent US-based company specializing in instrumentation, reagents, consumables, and software services. In September 2022, the company introduced Dynabeads Solutions, a revolutionary bead designed for scaling GMP-grade synthesis and purification of mRNA for vaccine development. The Dynabeads Streptavidin for In Vitro Transcription facilitates solid-phase IVT of cell-free mRNA, enabling the reuse of the DNA template up to six times. This innovation not only streamlines the plasmid creation process but also enhances mRNA yield on scales ranging from grams to grams. Consequently, it supports the development of a streamlined pipeline, enabling mRNA firms to expedite the transition from development to commercialization.
Major players in the mRNA synthesis raw materials market are actively engaged in the development of raw materials to boost their profitability and market share. Innovations in raw materials and their quality play a pivotal role in enhancing the efficiency, yield, and safety of mRNA synthesis processes, thereby influencing the overall success of applications in biotechnology and medicine. As an instance, in September 2022, TriLink BioTechnologies, a prominent US-based biotechnology company, introduced N1-Methyl-Pseudouridine-5'-Triphosphate, a crucial raw material in the production of various mRNA drugs. This innovative product facilitates accelerated drug discovery, meeting the rising demand for N1-methyl-pseudouridine modified mRNA. TriLink BioTechnologies' commitment to providing unmatched analytical capabilities and GMP-grade offerings underscores its dedication to advancing groundbreaking mRNA-based therapies globally.
In January 2022, Maravai LifeSciences, a United States-centered life sciences enterprise, completed the acquisition of MyChem for $240 million. This strategic acquisition is geared towards enhancing Maravai LifeSciences' array of nucleic acid production offerings and expediting its research and development capacities. MyChem, a company situated in the US, specializes in the manufacturing of nucleotides, making this acquisition a significant move for Maravai's expansion within this sector.
Major companies operating in the messenger ribonucleic acid (mRNA) synthesis raw materials market include Pfizer Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Moderna Inc., Agilent Technologies Inc., Lonza Group Ltd., Eurofins Scientific, Bio-Rad Laboratories Inc., Qiagen N.V., Maravai LifeSciences, Takara Bio Inc., GenScript Biotech Corporation, Promega Corporation, Abcam plc, BioLegend Inc., Integrated DNA Technologies Inc., Sino Biological Inc., CureVac N.V., LGC Biosearch Technologies, Enzo Biochem Inc, Merck KGaA, GeneCopoeia Inc., Bio-Synthesis Inc., BOC Sciences Inc, Bio Basic Inc., OriGene Technologies Inc., BioCat GmbH, Creative Biogene, Jena Bioscience GmbH, ATDBio Ltd.
North America was the largest region in the mRNA synthesis raw materials market in 2024. The regions covered in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The mRNA synthesis raw materials market consists of sales of modified ribonucleoside triphosphates, polynucleotide tails, ribonucleoside diphosphate (NDPs), ribonucleoside monophosphate (NMPs), and ribonucleoside triphosphate (NTTs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Messenger ribonucleic acid (mRNA) Synthesis Raw Materials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on messenger ribonucleic acid (mrna) synthesis raw materials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for messenger ribonucleic acid (mrna) synthesis raw materials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The messenger ribonucleic acid (mrna) synthesis raw materials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.